FDA Declines Approval for Omecamtiv Mecarbil in HFrEF

Citing a lack of efficacy data, the FDA has declined to approve omecamtiv mecarbil (Cytokinetics) for treatment of adults with chronic heart failure with reduced ejection fraction.
News Alerts